Reference

Last reviewed: 29 Apr 2026
Sources cited: 8

Compound class1,025.18 Da

Synthetic cyclic heptapeptide α-MSH analogue — melanocortin (MC3R/MC4R) receptor agonist

7-residue cyclic peptide with N-acetylation, a non-natural Nle (norleucine) residue, a D-Phe at position 4, and a side-chain cyclisation between Asp and Lys. The standard 3-letter sequence parser handles linear natural-amino-acid peptides only, hence the fallback.

PT-141 (Bremelanotide)

Last verified: 2026-04-29

At a glance


Also known as	Bremelanotide, Vyleesi (US trade name), PT-141 acetate
Class	Synthetic cyclic heptapeptide α-MSH analogue; melanocortin-receptor agonist (MC3R / MC4R)
Typical route	Subcutaneous injection on demand, 45 minutes before anticipated sexual activity
Half-life	~2.7 hours (terminal); central effect window 4–8 hours per dose
Molecular weight	1,025.18 Da
Sequence	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (7 residues, cyclised between Asp and Lys side chains; N-acetylated)
UK status	Not approved as a licensed medicine. Sold as a research chemical.
US status	FDA-approved as Vyleesi (2019) for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD). Prescription-only.6 Off-label use in men and postmenopausal women is at prescriber discretion.

What it is

PT-141 is one of the few compounds in this encyclopedia that acts on the central nervous system to produce a sexual effect rather than on peripheral hormones or vascular biology. It is a synthetic cyclic heptapeptide derived from α-MSH (alpha-melanocyte stimulating hormone), with the histidine and lysine residues cyclised to create a constrained, peptidase-resistant ring structure.

The compound binds melanocortin-4 receptors (MC4R) in the hypothalamus — specifically in the paraventricular nucleus — and the downstream effect is increased dopamine and oxytocin signalling in brain regions that mediate sexual desire and arousal. This is mechanistically different from sildenafil and tadalafil (which act on peripheral vascular smooth muscle to enable erection but don’t affect desire) and from testosterone (which acts on peripheral tissue sensitivity and slowly modulates central receptors). PT-141 is a brain-targeted desire/arousal compound.

It was approved by the FDA as Vyleesi in 2019 for premenopausal women with acquired, generalised HSDD (hypoactive sexual desire disorder) — a specific clinical population characterised by distressing low desire that wasn’t always present and isn’t situational. The pivotal Phase 3 trials (RECONNECT) enrolled 1,267 premenopausal women and showed modest but statistically significant improvement in desire and reduction in distress versus placebo.

The biohacker / research-chem community uses PT-141 off-label for similar indications in men (for desire-side erectile dysfunction not responsive to PDE-5 inhibitors), in postmenopausal women, and as a general “libido peptide” — all use cases that are not within the FDA-approved indication but rest on the same mechanistic basis. A meaningful subset of the off-label community is users for whom sildenafil and tadalafil don’t work — typically because the issue is desire/arousal rather than mechanical erectile function.

Mechanism

PT-141 is an agonist at melanocortin receptors, with selectivity for MC3R and MC4R over MC1R (which mediates skin pigmentation). The clinical effect is mediated primarily through MC4R in the hypothalamic paraventricular nucleus.2

The downstream cascade:

MC4R activation in the paraventricular nucleus of the hypothalamus
Dopamine release in the medial preoptic area — the dopaminergic pathway most directly tied to sexual motivation in mammalian models
Oxytocin release — the “social bonding” hormone, also implicated in sexual response
Net behavioural effect: increased sexual desire and arousal, distinct from the genital tissue response that PDE-5 inhibitors enable

The mechanism is independent of gonadal hormone levels. PT-141 works in users with normal testosterone or oestrogen, in users with low gonadal hormone levels, and in users for whom hormone replacement has failed to produce subjective desire effects. This is the central point of the compound’s value — it addresses the desire-side of the response, not the genital-mechanical side.

The MC1R activity is the reason for the hyperpigmentation side effect. PT-141 has higher affinity for MC4R than MC1R, but at typical clinical doses, MC1R activation is sufficient to drive measurable melanocyte stimulation in some users — particularly in fair-skinned users and with repeated dosing. This is the same mechanism that produces tanning effect with Melanotan II (a related compound covered separately in this encyclopedia). PT-141’s MC4R selectivity is higher than Melanotan II’s, so the pigmentation effect is smaller, but it’s not zero.

Routes of administration

Subcutaneous injection (the standard and approved route)


Bioavailability	Sufficient for the documented MC4R effects
Onset	30–45 minutes for subjective desire/arousal effect; peak at ~1–2 hours
Duration	4–8 hours of central effect; effect window typically reported as 4–6 hours of “ready state”
Typical dose (this route)	1.75 mg subQ as needed, maximum 1 dose per 24 hours, maximum 8 doses per month (per FDA label)1
Equipment (Vyleesi)	Pharmaceutical autoinjector pen, prefilled at 1.75 mg per dose, supplied by prescription
Equipment (research-chem)	Insulin syringe (29G–31G, U-100), bacteriostatic water, alcohol wipes
When this route makes sense	Default and standard. All clinical data and community use is subQ.

The 45-minute pre-activity timing is built into the FDA label and matches the pharmacokinetic window — peak central effect lands ~1–2 hours post-dose. Users who inject and immediately attempt sexual activity typically don’t get the full effect.

Intranasal (historical / discontinued)

PT-141 was originally developed as an intranasal formulation. The intranasal version was abandoned during clinical development because of dose-related blood pressure spikes; the subcutaneous formulation (Vyleesi) became the approved route. Some research-chem vendors sell intranasal PT-141 spray; the historical reason it was abandoned should weigh against using this route in any context.

Oral, sublingual, intramuscular

Not viable. PT-141 is GI-degraded; sublingual absorption is unreliable; IM offers no advantage over subQ. The compound was specifically designed for subQ administration in its approved formulation.

Cross-route comparison

SubQ on demand is the only meaningful route. The intranasal historical route was abandoned for blood-pressure safety reasons; sticking with subQ is both the licensed approach and the safest community practice.

What the evidence says

Honest summary: PT-141 has FDA-approval-grade Phase 3 evidence for HSDD in premenopausal women, with modest but statistically significant effects. Off-label use in men and postmenopausal women rests on smaller trials and pharmacology, not on the same evidence base. The safety profile is well-characterised at on-demand dosing but the long-term effects of chronic dosing are not.

Vyleesi RECONNECT Phase 3 trials (the approval evidence)

Two parallel Phase 3 randomised double-blind placebo-controlled trials enrolled 1,267 premenopausal women with HSDD and ran for 24 weeks of active treatment.5

Outcomes:

~25% of treated women reported clinically meaningful improvement in desire (vs ~17% on placebo)
Statistically significant reduction in distress related to low desire
Effect size was modest — clinically meaningful for the responders, but not transformative across the full population
Dose-dependent side effects — nausea (40%), flushing (20%), injection site reactions (13%), headache (11%)

The trial was powered to detect the modest effect size and the FDA approval reflects that. PT-141 is not “Viagra for women” — the popular framing — but a real if modest treatment for a specific clinical population.

Phase 2 trials in male erectile dysfunction (mixed results)

Earlier development included Phase 2 trials in men with erectile dysfunction. The compound showed efficacy in some PDE-5-non-responder subgroups but was not pursued for FDA approval in men, partly because PDE-5 inhibitors dominated that market and partly because the side-effect profile (especially blood-pressure increase) was harder to justify in a population with established alternative options.

The off-label use case in men is therefore mechanistically supported but not registrationally proven.

Safety profile

The 24-week RECONNECT trials documented:

Transient blood-pressure increase of ~6 mmHg systolic / ~3 mmHg diastolic post-dose, returning to baseline within 12 hours
Hyperpigmentation in some users, more common with frequent dosing (>8 doses/month)
Nausea dominantly on first dose, often improves with subsequent uses
No serious cardiovascular events at on-demand dosing levels in the trial population

The 8-doses-per-month maximum in the FDA label is specifically to limit hyperpigmentation accumulation and to bound the cumulative blood-pressure exposure. Chronic-daily dosing (which some research-chem users attempt) takes the compound outside the FDA-approved use pattern and into uncharacterised territory for both effects.

What the evidence does NOT show

No long-term outcome data beyond 24 weeks
No safety data on chronic-daily dosing — the approved use is on-demand, max 8/month
No registrational trials in men — efficacy in male ED is mechanistically plausible but not approval-grade
No data in postmenopausal women — the trial population was specifically premenopausal
No data in cardiovascular-disease populations — high CV risk is a relative contraindication on label
No comparison with PDE-5 inhibitors in mixed populations

Typical use patterns

On-label use (HSDD in premenopausal women, prescribed Vyleesi)

The FDA-approved protocol:

1.75 mg subQ via Vyleesi autoinjector, 45 minutes before anticipated sexual activity
Maximum 1 dose per 24 hours
Maximum 8 doses per month
Discontinue after 8 weeks if no improvement in desire / distress

Off-label community use

The biohacker / research-chem community uses PT-141 across populations the FDA approval doesn’t cover:

Men with desire-side ED or PDE-5-non-responsive ED
Postmenopausal women with HSDD-pattern presentation
Couples seeking enhanced libido / arousal effects (both partners using on demand)

The dose conventions vary:

Vyleesi-equivalent: 1.75 mg subQ on demand, matching the FDA-approved dose
Lower dose for women: 0.75–1 mg, which several practitioners report as effective with reduced nausea
Standard for men: 1.5–2 mg subQ on demand
Max frequency: typically respecting the 8-doses-per-month FDA limit even in off-label use, for hyperpigmentation reasons

Stacking

PT-141 is occasionally combined with PDE-5 inhibitors (sildenafil, tadalafil) in men where both desire and erectile function are issues. The mechanistic case is reasonable — different targets, complementary effects — but the combined blood-pressure effect needs caution. Both PT-141 and PDE-5 inhibitors can lower or alter blood pressure (in different directions); the net effect varies by individual and warrants prescriber input.

What the community gets right and wrong

The community use case in men with desire-side ED is mechanistically sound and represents a real unmet need (PDE-5 inhibitors don’t address desire). The use case in HSDD-equivalent presentations in postmenopausal women extrapolates the FDA-approved indication to a population the trial didn’t include — defensible mechanistically but with thinner evidence.

The “PT-141 as a recreational libido peptide” framing — couples both dosing for shared experiences — is the use case furthest from the trial evidence and accumulates the most cumulative side-effect risk (hyperpigmentation, blood pressure) when frequency exceeds the FDA-label maximum.

For sensitive systems

PT-141 has a distinct sensitive-systems profile because it acts centrally on the melanocortin system, which is implicated in autonomic regulation, food intake, and immune function beyond its sexual effects.

Start dose for sensitive users. 0.5–0.75 mg subQ for the first dose. The dominant first-dose side effect (nausea) is dose-related, and starting low lets the user identify their tolerance without committing to the full 1.75 mg first-time experience.

Ramp. If 0.75 mg is well tolerated, 1.0–1.5 mg for subsequent doses is reasonable. Many sensitive users find sub-1.75 mg doses sufficient; the dose-response curve flattens above 1.5 mg in practice.

Expected adjustment profile:

Nausea — the dominant effect, especially on first dose. Approximately 40% of trial participants reported nausea; usually improves with subsequent doses. Lasts 2 hours or more in some users.
Flushing and warmth — common, melanocortin-mediated.
Injection-site reactions — pain, redness, swelling. Local and transient.
Headache — present in ~11% of trial participants.
Transient blood-pressure increase — ~6/3 mmHg systolic/diastolic post-dose, resolves within 12 hours.
Hyperpigmentation — darkening of skin (face, gums, breasts) with repeated use, particularly above 8 doses/month. May not resolve fully on discontinuation.

What’s not normal and warrants stopping: prolonged blood-pressure elevation beyond 12 hours, palpitations, atypical chest sensations, severe or persistent headache, vision changes, syncope or near-syncope, persistent nausea beyond 8 hours, symptoms suggesting allergic reaction (rash, swelling beyond injection site).

For MCAS / histamine-sensitive users. No specific histamine activity documented but the flushing effect is real and melanocortin-mediated rather than mast-cell-mediated. Most MCAS users tolerate PT-141 if they tolerate the nausea. Be aware: the flushing pattern can mimic a mast-cell reaction, which can be confusing for users tracking sensitive-systems symptoms.

For POTS users. Worth specific caution. The transient blood-pressure increase is meaningful in users whose autonomic system is already dysregulated. Some POTS users tolerate PT-141 fine; others find the BP transient produces orthostatic worsening or palpitations beyond what’s tolerable. Sensitive-start dosing (0.75 mg) and monitoring HR/BP for 4 hours post-dose is the cautious approach.

For users with hypertension. Relative contraindication. The FDA label specifically warns against PT-141 in patients with uncontrolled hypertension or known cardiovascular disease. The transient BP increase is small in absolute terms but stacks with existing elevation. Users with hypertension should consult a prescriber before using PT-141.

For users on antihypertensive medication. No documented interaction but the BP effect makes monitoring worthwhile, especially for users on multiple antihypertensives.

For users with melanoma history or family history of melanoma. Relative contraindication. The MC1R activity that drives hyperpigmentation is theoretically relevant to melanocyte biology generally. PT-141 has not been studied in melanoma populations and the prudent posture for users with personal or family history is to choose a different approach.

For pregnancy and breastfeeding. Contraindicated per FDA label.

Interactions worth considering:

PDE-5 inhibitors (sildenafil, tadalafil): mechanistically complementary; combined BP effects need monitoring.
Antihypertensives: monitor BP.
Other melanocortin agonists (Melanotan II): redundant; do not stack — same receptor system.
Alcohol: the FDA label notes potential additive effects on hypotension/dizziness; moderate use is reasonable but not encouraged in close proximity to dosing.
Antiemetics: some users pre-dose with low-dose ondansetron 30–60 minutes before PT-141 to mitigate the first-dose nausea.

Reasonable expectations

Onset. Subjective desire/arousal effect is typically noticed 30–60 minutes after subQ injection, peaking at 1–2 hours. The 45-minute pre-activity timing in the FDA label aligns with this onset.

Response rate. In the registrational trials, ~25% of treated women reported clinically meaningful improvement in desire (vs ~17% on placebo — so the net response rate attributable to PT-141 was modest). Off-label male and postmenopausal female response rates are not directly characterised but community reports describe similar magnitude — meaningful for responders, modest in absolute terms.

What the evidence actually supports.

Modest improvement in subjective desire and arousal in HSDD populations.
Statistically significant distress reduction in the trial population.
MC4R-mediated central mechanism producing dopamine and oxytocin elevation.
Effect independent of gonadal hormone levels.

What the evidence does not support.

Reliable erectile-function effect comparable to PDE-5 inhibitors — different mechanism, different effect; some users get both benefits, but PT-141 is not a substitute for sildenafil/tadalafil for mechanical erectile function.
Long-term benefit beyond 24 weeks of on-demand use.
Recreational-grade libido enhancement — the effect is real but modest; “Viagra for women” framing overstates it.

What not to expect.

Immediate effect. The 45-minute onset is real; users who inject and immediately attempt activity won’t get the full effect.
Reliable effect every dose. Even responders don’t respond to every dose; non-responders don’t develop response with continued use.
No side effects. Nausea on first dose is the rule, not the exception.
Indefinite use without consequence. Hyperpigmentation accumulates with frequent dosing.

Cost

US (Vyleesi — FDA-approved prescription)

Vyleesi is dispensed through specialty pharmacies on prescription. Approximate pricing (2026, US, varies by insurance and pharmacy):

Component	Typical cost
Vyleesi autoinjector (1 dose)	~$100–250 per single-dose autoinjector at retail
4-pack of autoinjectors	~$400–900
Insurance coverage	Variable; commercial insurance may cover with prior auth, Medicare/Medicaid coverage limited

Research-chemical (UK and US)

PT-141 is widely available through peptide research-chem vendors:

10 mg vials: ~£25–60 / $30–75
Monthly cost at 1.75 mg per use, 4 uses/month: roughly £15–40 / $20–50

The research-chem cost-per-dose is dramatically lower than the pharmaceutical pen, which is the central economic driver for off-label community use even in markets where Vyleesi is available.

Sensitive-start economics

A user starting at 0.75 mg per dose uses about 40% of the full 1.75 mg dose. A 10 mg vial covers ~13 sensitive-start doses, comfortably within the 30-day reconstituted shelf life.

Reconstitution

This section covers reconstitution of research-chemical PT-141. Vyleesi arrives as a prefilled autoinjector pen and requires no preparation — if that’s your route, skip this section.

What’s in the box

Research-chemical PT-141 ships as lyophilised white powder in a glass vial, typically 10 mg per vial (the dominant size; 5 mg also available). Equipment is the same as for the GH cluster: BAC water, U-100 insulin syringe, larger transfer syringe, alcohol wipes.

The math

10 mg vial, 2 mL BAC water (the standard)

Concentration: 5 mg/mL (5,000 mcg/mL)
0.75 mg sensitive-start = 0.15 mL = 15 units
1 mg = 0.2 mL = 20 units
1.5 mg = 0.3 mL = 30 units
1.75 mg (Vyleesi-equivalent) = 0.35 mL = 35 units
2 mg = 0.4 mL = 40 units

10 mg vial, 1 mL BAC water (for users at full doses who want fewer units to draw)

Concentration: 10 mg/mL
1.75 mg = 0.175 mL = 17–18 units
A more concentrated draw, but smaller absolute volume can be harder to read accurately on a U-100 syringe at low doses.

5 mg vial, 1 mL BAC water (for sensitive-start protocols)

Concentration: 5 mg/mL
0.5 mg = 0.1 mL = 10 units
0.75 mg = 0.15 mL = 15 units

The Peptrax Vial Plan calculator handles the same math interactively.

Reconstitution procedure

Wipe the rubber stopper of the lyophilised vial and the BAC water vial with alcohol.
Draw the chosen volume of BAC water into the larger syringe.
Insert the needle into the lyophilised vial at an angle, with the tip touching the inside wall above the powder. Inject the water slowly down the inside of the vial, not directly onto the powder.
Leave the vial undisturbed for 1–2 minutes. Do not shake. Gently swirl if needed.
Once the solution is clear, label the vial: compound, concentration, reconstitution date.
Store refrigerated (2–8°C / 36–46°F).

Some practitioners pass the reconstituted solution through a 0.22 µm syringe filter as a belt-and-braces sterility step.

Storage and stability

PT-141 reconstituted with BAC water is stable for ~28–30 days refrigerated — at the longer end of the research-chem peptide range, similar to semaglutide and tirzepatide. Most vendor-quoted figures and community sources converge around 30 days.

Conservative: 21 days refrigerated
Middle: 28–30 days refrigerated
Optimistic: 30+ days

Store at the back of the refrigerator. Do not freeze.

If you reconstitute with plain sterile water instead of BAC water, the vial is single-use — discard within 24 hours.

For a 10 mg vial dosed at 1.75 mg per use, you have ~5–6 doses per vial. At the 8-doses-per-month FDA-label maximum, a 10 mg vial covers most of a month with one vial reconstituted at the start. Lower-frequency users will discard product if they don’t pace dosing within the 30-day window.

What gets miscalculated

mg vs mcg confusion — PT-141 doses are in mg.
Reading “units” as mg — units are a volume mark.
Skipping the 45-minute pre-activity timing — peak effect is at 1–2 hours, not at the moment of injection.
Exceeding 8 doses/month — the FDA label maximum is specifically about hyperpigmentation accumulation. Off-label users who exceed this are taking on cumulative side-effect risk.
Reconstituting with intent to use intranasally — the historical intranasal route was abandoned for blood-pressure safety reasons; subQ is the appropriate route.

Areas of concern ⚠

Cardiovascular — transient blood pressure increase

PT-141 produces a documented transient blood-pressure increase of ~6 mmHg systolic / ~3 mmHg diastolic post-dose, resolving within 12 hours. This is small in absolute terms but is the primary cardiovascular safety consideration.

The FDA label specifies:

Contraindicated in users with uncontrolled hypertension or known cardiovascular disease
Monitor blood pressure if used in users with controlled hypertension
Discontinue if BP elevation persists beyond 12 hours

For users with significant cardiovascular risk factors, PT-141 is a relative contraindication in the absence of cardiac workup.

Hyperpigmentation accumulation

The MC1R activity drives skin-pigmentation effects that accumulate with repeated dosing. The FDA label specifies a maximum of 8 doses per month specifically to bound this risk. Hyperpigmentation may not fully resolve on discontinuation — it can be permanent in some users.

Affected sites: face, gums, breasts most commonly; new naevi (moles) have been reported with extended high-frequency use.

Melanoma risk theoretical

The MC1R activation is the same pathway implicated in melanocyte biology. PT-141 has not been studied in melanoma populations and is relatively contraindicated for users with personal or family history of melanoma. The risk-benefit is unfavourable — alternative approaches to sexual dysfunction exist for these users.

Long-term safety beyond 24 weeks not established

The pivotal trials ran 24 weeks of on-demand dosing. Long-term effects of regular dosing over years are uncharacterised. Mechanistic concerns include:

Cumulative hyperpigmentation
Cumulative cardiovascular exposure even if each individual dose’s BP effect is transient
Unknown effects of chronic MC4R activation on appetite regulation (MC4R is the same receptor implicated in genetic obesity syndromes)

Quality and sourcing

For US patients with Vyleesi prescription: pharmaceutical-grade, supply-chain-verified. For research-chem users: standard caveats apply — variable purity, no oversight at point of sale. Lab-tested vendors with mass-spec or HPLC certificates are the meaningful quality marker. PT-141’s relatively short 7-residue peptide structure is easier to synthesise at high purity than the longer GHRH analogues, so quality issues are less common but not absent.

Populations where PT-141 is contraindicated or high-risk

Uncontrolled hypertension — contraindicated per FDA label
Known cardiovascular disease — contraindicated per FDA label
Melanoma history (personal or family) — relative contraindication
Pregnancy and breastfeeding — contraindicated
Under 18 — not studied; off-label
Severe renal or hepatic impairment — limited data; caution
Users with significant naevus burden / dysplastic naevus syndrome — caution; pigmentation effects may be more pronounced

Measurement and dosing pitfalls

mg vs mcg confusion. PT-141 doses are 1–2 mg, not mcg.
Exceeding 8 doses/month. This is a hyperpigmentation-bound limit, not arbitrary.
Stacking with Melanotan II. Both compounds activate the melanocortin system; stacking accelerates pigmentation accumulation and produces additive blood-pressure effects.
Using intranasal preparations. The historical intranasal formulation was abandoned for BP safety reasons.

What the community gets wrong

“Viagra for women / men.” Mechanistically different from PDE-5 inhibitors. PT-141 affects desire and central arousal; sildenafil affects peripheral vascular response. They’re not substitutes for each other and they don’t address the same problem.
“Use as often as you want.” The 8-doses-per-month FDA limit reflects real cumulative risks (hyperpigmentation, BP exposure). Off-label users who exceed this take on documented risk.
“No side effects at low dose.” Nausea on first dose is the dominant effect and is largely independent of dose within the therapeutic range.
“Tans you up as a bonus.” The pigmentation effect is the side effect that requires the dose limit. Treating it as a benefit accelerates accumulation in unpredictable patterns (face, gums, breasts) that often aren’t aesthetic.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Approved as Vyleesi (2019) for premenopausal women with acquired, generalised HSDD. Prescription-only. Off-label use in men and postmenopausal women is at prescriber discretion.	2026-04-29
UK (MHRA)	Not approved as a licensed medicine. No NHS or private-prescription pathway. Sold as a research chemical under “research use only” labelling.	2026-04-29
EU (EMA)	Not approved. Vyleesi was withdrawn from EU regulatory pursuit; no current licensed product.	2026-04-29
Australia	Not approved by TGA. Available through Special Access Scheme on individual basis.	2026-04-29
WADA (sport)	Not specifically prohibited as of the 2026 list. PT-141 does not fall under the standard prohibited categories.	2026-04-29

Narrative. PT-141’s regulatory pathway is selective — FDA-approved for one specific indication in one population, with off-label use legal at prescriber discretion. The UK has no licensed pathway; research-chemical purchase is the only access route. Compared to the GH-cluster compounds, PT-141 has the advantage of clear FDA-approval status (in the US, for the on-label indication) but the same grey-market access issues outside that path.

What to track in Peptrax

PT-141 fails for plenty of users who are simply dosing 15 minutes before activity instead of 45 — the onset window is real and unforgiving. Logging the time gap between injection and intended use is the first piece of attribution: if “PT-141 didn’t work,” check whether the user’s actually testing the compound or testing a timing miss.

For most users, the highest-signal log is per-use efficacy and side-effect profile: did the dose produce the desired desire/arousal effect, was nausea present, was there flushing, did the user notice any pigmentation changes over time. Unlike most compounds in this encyclopedia, PT-141 is on-demand rather than continuous — so the relevant tracking unit is the individual dose, not the day or week.

For sensitive-systems users, the priority log shifts to cardiovascular markers in the hours after dosing — BP, HR, any orthostatic symptoms. The transient BP increase resolves within 12 hours, but in users with autonomic dysregulation (POTS) or controlled hypertension, the size of that transient matters and is worth measuring.

Across all users, monthly dose count is non-negotiable to track because the 8-doses-per-month FDA limit is hyperpigmentation-bound, not arbitrary. The app should help users see “this is your 7th dose this month; the FDA-label maximum is 8 for cumulative safety reasons.” Pigmentation changes over time (photographing common sites — face, gums — periodically) is a tracking pattern most users don’t think to set up but is the only way to catch the accumulation early.

For personal tracking and informational purposes only — not medical advice.